Category - News

Developments

Positive buzz on new prostate disease treatment, TULSA-PRO, coming out of RSNA annual meeting

According to a number of trade media reports, Profound Medical’s (NASDAQ:PROF; TSX:PRN) recently 510(k)-cleared TULSA-PRO system received high marks at the Radiology Society of North America (RSNA) annual meeting. TULSA...

December 6, 2019

Markets

HCW starts Puma Biotechnology at buy; PT $15

H.C. Wainwright launched coverage of Puma Biotechnology (NASDAQ:PBYI) with a “buy” rating and $15 price target. The stock closed at $7.44 on Dec. 5. Puma has a marketed drug called Nerlynx, which was approved by the FDA...

December 6, 2019

Developments

Omeros reports positive data from pivotal narsoplimab trial

Omeros (NASDAQ:OMER) reported positive data from its pivotal clinical trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). HSCT-TMA occurs when...

December 5, 2019

Developments

Rhythm Pharma completes enrollment in Phase 3 setmelanotide trial

Rhythm Pharmaceuticals (NASDAQ:RYTM) completed enrollment of the pivotal cohort in its Phase 3 trial of setmelanotide for the treatment of insatiable hunger and severe obesity in Bardet-Biedl syndrome (BBS) or Alström...

December 5, 2019

Developments

Anavex presents two-year data from Phase 2a AD trial

Anavex Life Sciences (NASDAQ:AVXL) presented interim two-year data from its Phase 2a extension study of ANAVEX2-73 in Alzheimer’s disease (AD) patients at the 2019 clinical trials on AD conference. ANAVEX2-73 is...

December 5, 2019

Developments

Aptinyx begins Phase 2 study of Parkinson’s disease-associated mild cognitive impairment

Aptinyx (NASDAQ:APTX) launched a Phase 2 study of NYX-458 for the treatment of mild cognitive impairment associated with Parkinson’s disease (PD). NYX-458 is an n-methyl-d-aspartate, or NMDA, receptor modulator. The 135...

December 5, 2019

Developments

Ra Pharma doses first patient in Phase 2 immune-mediated necrotizing myopathy study

Ra Pharmaceuticals (NASDAQ:RARX) dosed the first patient in its Phase 2 clinical trial evaluating zilucoplan for the treatment of immune-mediated necrotizing myopathy (IMNM). IMNM is an autoimmune disease characterized...

December 5, 2019

Markets

Dawson James removes PT for ADMA Biologics

Dawson James Securities removed its prior $4 price target for ADMA Biologics (NASDAQ:ADMA) after the company reported third quarter financial results. The stock was changing hands at $4.09 in afternoon trading on Dec. 5...

December 5, 2019

Markets

Dawson James starts Check Cap at buy; PT $4

Dawson James Securities initiated coverage of Check Cap (NASDAQ:CHEK) with a “buy” rating and $4 price target. The stock closed at $1.39 on Dec. 4. The company has developed an imaging technology’ known as C-Scan, using...

December 5, 2019

Developments

Hummingbird Bioscience raises $19-million in Series B financing

Closely-held Hummingbird Bioscience raised $19-million in a Series B financing round co-led by Mirae Asset Venture Investment and GNTech Venture Capital. Existing investors Heritas Capital and Seeds Capital also...

December 5, 2019

Category - News

Positive buzz on new prostate disease treatment, TULSA-PRO, coming out of RSNA annual meeting

HCW starts Puma Biotechnology at buy; PT $15

Omeros reports positive data from pivotal narsoplimab trial

Rhythm Pharma completes enrollment in Phase 3 setmelanotide trial

Anavex presents two-year data from Phase 2a AD trial

Aptinyx begins Phase 2 study of Parkinson’s disease-associated mild cognitive impairment

Ra Pharma doses first patient in Phase 2 immune-mediated necrotizing myopathy study

Dawson James removes PT for ADMA Biologics

Dawson James starts Check Cap at buy; PT $4

Hummingbird Bioscience raises $19-million in Series B financing

General

More